TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26096029

Group type: EXPERIMENTAL
Intervention: eSET
Number of subjects: 65

Group type: COMPARATOR
Intervention: eDET
Number of subjects: 65
Study: 25607706

Group type: EXPERIMENTAL
Intervention: Ivermectin 1% cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azelaic acid 15% gel
Number of subjects: 0
Study: 23066119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: 30,000 IU vitamin D(3)
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: 60,000 IU vitamin D(3)
Number of subjects: 644
Study: 19208350

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day for 1 month (increased to 40 mg/day at day 15)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Simvastatin with beta-adrenergic blockers
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Simvastatin without beta-adrenergic blockers
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 17554116

Group type: EXPERIMENTAL
Intervention: Eprodisate
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 15168839

Group type: EXPERIMENTAL
Intervention: Mixed Episode
Number of subjects: 152

Group type: COMPARATOR
Intervention: Manic Episode
Number of subjects: 152
Study: 12063011

Group type: EXPERIMENTAL
Intervention: Ala-9Val polymorphism in SOD2 gene
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (patients with no clinically detectable reaction)
Number of subjects: 80
Study: 9469328

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 551

Group type: COMPARATOR
Intervention: Megestrol acetate (MA) 160 mg
Number of subjects: 551

Group type: COMPARATOR
Intervention: Letrozole 0.5 mg
Number of subjects: 551
Study: 7818160

Group type: EXPERIMENTAL
Intervention: Patients with precocious coronary heart disease (CHD)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: First-degree relatives of patients with CHD
Number of subjects: 107

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Patients with CAD
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: First-degree relatives of patients with CAD
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: First-degree relatives of hyperlipidemic patients
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Families studied
Number of subjects: 107
Study: 2120639

Group type: EXPERIMENTAL
Intervention: 0.5 mg h‐1 intra‐arterial rt‐PA
Number of subjects: 17

Group type: COMPARATOR
Intervention: 5000 units h‐1 Sk and 250 units h‐1 heparin intra‐arterially
Number of subjects: 17
Study: 224083

Group type: EXPERIMENTAL
Intervention: Stannous fluoride dentifrice in a silica gel base
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Stannous fluoride dentifrice in a calcium pyrophosphate base
Number of subjects: 1339

Group type: COMPARATOR
Intervention: Nonfluoride control dentifrice
Number of subjects: 1339
Study: 29967948

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB) with 4 mg/kg sugammadex at post-tetanic count (PTC) of 2
Number of subjects: 108

Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (NMB) with 2 mg/kg sugammadex at a train-of-four (TOF) count of 1 or 2
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups (Deep NMB and Moderate NMB)
Number of subjects: 108
Study: 28854592

Group type: EXPERIMENTAL
Intervention: Weight reduction intervention followed by IVF treatment; 12 weeks of low calorie liquid formula diet (LCD) of 880 kcal/day followed by weight stabilization for 2-5 weeks.
Number of subjects: 317

Group type: COMPARATOR
Intervention: IVF treatment only.
Number of subjects: 317
Study: 26014321

Group type: EXPERIMENTAL
Intervention: STAR maneuver
Number of subjects: 35

Group type: COMPARATOR
Intervention: ART method
Number of subjects: 35
Study: 23897918

Group type: EXPERIMENTAL
Intervention: Nasal tube
Number of subjects: 363

Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 363
Study: 21157393

Group type: EXPERIMENTAL
Intervention: Isometric exercises (prone bridge [PB] and superman [SM])
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dynamic exercises (back squat, front squat [FS], and military press)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Front squat (FS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isometric exercises (PB)
Number of subjects: 10
Study: 19554082

Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-6
Number of subjects: 5680

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 5680

Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 5680

Group type: COMPARATOR
Intervention: Traditional risk factors
Number of subjects: 5680
Study: 17719320

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sodium chloride
Number of subjects: 59
Study: 15507794

Group type: EXPERIMENTAL
Intervention: assess/advise/treat group
Number of subjects: 102

Group type: COMPARATOR
Intervention: assess/advise/wait group
Number of subjects: 102
Study: 11480656

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral insomnia therapy (CBT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Progressive muscle relaxation training
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham behavioral intervention
Number of subjects: 75
Study: 9926274

Group type: EXPERIMENTAL
Intervention: salbutamol 8 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: atenolol 50 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: pindolol 10 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 8059623

Group type: COMPARATOR
Intervention: Control patients attending the UNC Family Practice Center for a routine Papanicolaou smear
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Interventions made to inform control patients of the risk of HPV and need for closer follow-up
Number of subjects: 373
Study: 3058043

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin 2 (IL2) administered intravenously at doses of 1 x 10(4), 3.3 ‐ 5 x 10(4), 1 x 10(5), 3.3‐5 x 10(5), 1 x 10(6) and 3.3 x 10(6) U/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin 2 (IL2) administered subcutaneously at a dose of 1 x 10(6) U/day for 5 days
Number of subjects: 40
Study: 31378111

Group type: EXPERIMENTAL
Intervention: Group rational emotive behavioural intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 29236529

Group type: EXPERIMENTAL
Intervention: Warnings on red backgrounds
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Warnings on white backgrounds
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Warnings with greater size (20%, 30%, or 50%)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: E-cigarette users
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Attention to warning labels
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Warning message recall
Number of subjects: 544
Study: 28386837

Group type: EXPERIMENTAL
Intervention: Prostacyclin infusion
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 25403646

Group type: EXPERIMENTAL
Intervention: LCZ696 (400 mg daily)
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Enalapril (20 mg daily)
Number of subjects: 8399
Study: 22782459

Group type: EXPERIMENTAL
Intervention: Celecoxib plus risperidone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo plus risperidone
Number of subjects: 40
Study: 21728004

Group type: EXPERIMENTAL
Intervention: Berbamine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (no berbamine)
Number of subjects: 63
Study: 19061537

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS), 110 microg/day, once daily
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray (FPNS), 200 microg/day, twice daily
Number of subjects: 446

Group type: COMPARATOR
Intervention: FFNS placebo
Number of subjects: 446

Group type: COMPARATOR
Intervention: FPNS placebo
Number of subjects: 446
Study: 16505427

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 U subcutaneously weekly (40K arm)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Epoetin alfa 120,000 U subcutaneously every 3 weeks (120K arm)
Number of subjects: 365
Study: 15284376

Group type: EXPERIMENTAL
Intervention: 10 mg/d of elemental iron alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 10 mg/d of elemental iron in combination with multimicronutrients
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 11052409

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) at a mean dose of 80 mg (1.8 mg/kg/day) during the open phase
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) during the discontinuation phase
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo during the discontinuation phase
Number of subjects: 35
Study: 9333770

Group type: EXPERIMENTAL
Intervention: TSH-receptor antibodies (TRAb) detection
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Thyroperoxidase antibodies (TPO‐Ab) estimation
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Thyrostatic treatment of Graves' disease
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Subtotal thyroidectomy
Number of subjects: 313
Study: 8039151

Group type: EXPERIMENTAL
Intervention: Vinorelbine plus doxorubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin, and 5-FU (CEF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CEF with G-CSF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 0
Study: 2768607

Group type: EXPERIMENTAL
Intervention: Slide/tape program presenting procedures involved in cesarean delivery
Number of subjects: 42

Group type: COMPARATOR
Intervention: Neutral information program
Number of subjects: 42
Study: 869291

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 52

Group type: COMPARATOR
Intervention: Xanthinol nicotinate
Number of subjects: 52
Study: 31855037

Group type: EXPERIMENTAL
Intervention: Metacognitive Training (MCT)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Psychoeducational intervention
Number of subjects: 122
Study: 30146591

Group type: EXPERIMENTAL
Intervention: SSRI (paroxetine, escitalopram)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: SNRI (duloxetine)
Number of subjects: 55
Study: 28017188

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Manual Pressure (MP)
Number of subjects: 42
Study: 27177778

Group type: EXPERIMENTAL
Intervention: Food advertising literacy program (Experimental Group A)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Comparable knowledge-based nutrition education program (Experimental Group B)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no nutrition education)
Number of subjects: 140
Study: 23828464

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.15%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.1%
Number of subjects: 60
Study: 20707790

Group type: EXPERIMENTAL
Intervention: Trospium chloride 60 mg extended release (ER)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 19362676

Group type: EXPERIMENTAL
Intervention: Avotermin 50 ng/100 microL per linear cm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avotermin (various concentrations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avotermin 500 ng/100 microL per linear cm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16549856

Group type: EXPERIMENTAL
Intervention: Prostate cancer screening using PSA criteria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PSA threshold below 4.0 ng/mL
Number of subjects: 0
Study: 14565966

Group type: EXPERIMENTAL
Intervention: Heavy-load strength training (80% of maximum, n = 11)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Heavy-load steadiness training (n = 6)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Heavy-load strength training and Heavy-load steadiness training
Number of subjects: 26

Group type: COMPARATOR
Intervention: No training (n = 9)
Number of subjects: 26
Study: 11352075

Group type: EXPERIMENTAL
Intervention: Continuous vectorcardiography (cVCG) for 24 hours after admission, performed on 730 patients.
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Continuous 12-lead electrocardiography (c12ECG) for 24 hours after admission, performed on 286 patients.
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Comparison of cVCG and c12ECG results.
Number of subjects: 1016
Study: 8691967

Group type: EXPERIMENTAL
Intervention: d-sotalol (100 mg increased to 200 mg twice daily, if tolerated)
Number of subjects: 3121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3121

Group type: EXPERIMENTAL
Intervention: d-sotalol
Number of subjects: 3121
Study: 1755948

Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chlorprothixene (30 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clonidine (75 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketotifen (3 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg)
Number of subjects: 12
Study: 6296465

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (1 gm every 12 hours)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cefamandole (1 gm every 6 hours)
Number of subjects: 21
Study: 31814316

Group type: EXPERIMENTAL
Intervention: Morning walking group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Afternoon walking group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 30292734

Group type: EXPERIMENTAL
Intervention: ADS-5102 (amantadine)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 27824277

Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis DSM17250 extract (ointment formulation)
Number of subjects: 0
Study: 24532827

Group type: EXPERIMENTAL
Intervention: Multitiered intervention with enhanced core reading instruction and additional 30-min daily small group intervention
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control condition with standard Tier 1 instruction (90 min whole group instruction)
Number of subjects: 267
Study: 22963894

Group type: EXPERIMENTAL
Intervention: Ramelteon
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 21722952

Group type: EXPERIMENTAL
Intervention: txt2stop intervention (motivational messages and behavioural-change support)
Number of subjects: 5800
Study: 19290689

Group type: EXPERIMENTAL
Intervention: Behavioral Naltrexone Therapy (BNT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Compliance Enhancement (CE)
Number of subjects: 64
Study: 17668969

Group type: EXPERIMENTAL
Intervention: 0.454% SnF2/sodium hexametaphosphate dentifrice
Number of subjects: 440

Group type: COMPARATOR
Intervention: Sodium fluoride/0.30% triclosan/copolymer dentifrice
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 440
Study: 15151728

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 248

Group type: COMPARATOR
Intervention: IVF
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: IVF/ICSI (combined approach)
Number of subjects: 248
Study: 12026536

Group type: EXPERIMENTAL
Intervention: SIT (Specific Immunotherapy) with mixed grass pollen allergens (Allergovit, Pollinex)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: SIT (Specific Immunotherapy) with mixed grass pollen allergens
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (before SIT)
Number of subjects: 27
Study: 9824782

Group type: EXPERIMENTAL
Intervention: Intravenous morphine 0.05 mg/kg (3.5 mg for 70-kg body weight)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7813412

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) monotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Phenytoin (PHT) monotherapy
Number of subjects: 50
Study: 2221587

Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 13
Study: 92624

Group type: EXPERIMENTAL
Intervention: Immune plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal plasma
Number of subjects: 0
Study: 31155392

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (0.5 mg/kg/6 hours)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 35
Study: 27460280

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX implant)
Number of subjects: 573
Study: 25844993

Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 939

Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C
Number of subjects: 939
Study: 23683790

Group type: EXPERIMENTAL
Intervention: Baseline fMRI scan including a cocaine‐cue reactivity task and a go no‐go response inhibition task
Number of subjects: 30
Study: 21402578

Group type: EXPERIMENTAL
Intervention: Behavioural sleep strategies delivered over one to three structured individual nurse consultations from 8 to 10 months
Number of subjects: 328

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 328
Study: 19473201

Group type: EXPERIMENTAL
Intervention: Pocket PATH
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 30
Study: 17681066

Group type: EXPERIMENTAL
Intervention: Potassium sensitivity test (PST)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bladder biopsy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bladder cystoscopy
Number of subjects: 35
Study: 14722400

Group type: EXPERIMENTAL
Intervention: Cylindrical threaded titanium cage device
Number of subjects: 140

Group type: COMPARATOR
Intervention: Femoral ring allograft control
Number of subjects: 140
Study: 11313615

Group type: EXPERIMENTAL
Intervention: Chiropractic adjustment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sham adjustment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study: 9222076

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 100 mg tablets (fasted)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alatrofloxacin (IV infusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 100 mg tablets (after standard breakfast)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Trovafloxacin 300 mg oral aqueous suspension (fasted)
Number of subjects: 12
Study: 8107542

Group type: EXPERIMENTAL
Intervention: Rehydration with 1.5 l of water over 2 h after 24 h of dehydration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Euhydrated trial (ET)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rehydration trial (RT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dehydration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rehydration
Number of subjects: 8
Study: 3105747

Group type: EXPERIMENTAL
Intervention: Normal protein diet (median 92 g/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low protein diet (47 g/day)
Number of subjects: 8
Study: 29473700

Group type: EXPERIMENTAL
Intervention: C-isotope breath analysis (13 C breath tests)
Number of subjects: 15

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 15
Study: 27989522

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy with hiatal hernia repair
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sleeve gastrectomy without hiatal hernia repair
Number of subjects: 100
Study: 24472873

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy targeting normal‐for‐age fasting blood glucose concentrations
Number of subjects: 100

Group type: COMPARATOR
Intervention: Insulin infusion only to prevent excessive hyperglycemia
Number of subjects: 100
Study: 22440371

Group type: EXPERIMENTAL
Intervention: 1μg.kg(‐1) dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3μg.kg(‐1) fentanyl
Number of subjects: 60
Study: 19397435

Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cultural adaptations
Number of subjects: 0
Study: 17488454

Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 90

Group type: COMPARATOR
Intervention: exfoliation syndrome
Number of subjects: 90
Study: 15159198

Group type: EXPERIMENTAL
Intervention: Forearm support using the desk surface (Group 1)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Forearm support (after 6 weeks for Group 2)
Number of subjects: 59
Study: 12234955

Group type: EXPERIMENTAL
Intervention: Paxil (20 mg/d) for 6 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 25
Study: 9637806

Group type: EXPERIMENTAL
Intervention: Metformin plus Clomiphene
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo plus Clomiphene
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Metformin alone
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 61
Study: 7992821

Group type: EXPERIMENTAL
Intervention: Extract of Panax ginseng
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extract of Panax quinquefolium roots
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extract of Ganoderma lucidum
Number of subjects: 0
Study: 2532847

Group type: EXPERIMENTAL
Intervention: Acitretin
Number of subjects: 168

Group type: COMPARATOR
Intervention: Etretinate
Number of subjects: 168
Study: 6388901

Group type: EXPERIMENTAL
Intervention: Stepped care group
Number of subjects: 7825

Group type: COMPARATOR
Intervention: Referred care group
Number of subjects: 7825
Study: 31401237

Group type: COMPARATOR
Intervention: Food odors signaling sweet, savory, and sour taste (study 1)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Food odors signaling carbohydrates, protein, fat, and low-calorie food (study 2)
Number of subjects: 96
Study: 28418492

Group type: EXPERIMENTAL
Intervention: PTM intervention (5 group workshops: 2 by audiologist, 3 by psychologist)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: PTM intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 300